Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 4/2018

EFFECTIVENESS OF SUBCONJUNCTIVAL BEVACIZUMAB ASSOCIATED WITH A LASER – BASED PROCEDURE IN THE TREATMENT OF NEOVASCULAR GLAUCOMA

MARIA ALEXANDRA PREDA 1#, GHEORGHITA POPA 1#, OLIMPIU L. KARANCSI 2#*, OVIDIU MUSAT 3#, STELLA IOANA POPESCU 3#, MIHNEA MUNTEANU 1#, ZORAN POPA 4#

1.Department of Ophthalmology, “Victor Babeş” University of Medicine and Pharmacy, Timișoara, Romania
2 .Department of Oral Implantology and Prosthetic Restorations on Implants, “Victor Babes” University of Medicine and Pharmacy, Timișoara, Romania
3 .Department of Ophthalmology, “Dr. Carol Davila” Central Military Emergency University Hospital, Bucharest, Romania
4 .Department of Obstetrics and Gynaecology, “Victor Babes” University of Medicine and Pharmacy, Timișoara, Romania

Download Full Article PDF

Micropulse transscleral diode laser cyclophotocoagulation (mTSCPC) is an established method of treatment for refractory glaucoma. This study evaluates the efficacy and safety of subconjunctival bevacizumab associated with mTSCPC versus mTSCPC alone. A number of six patients with neovascular glaucoma were treated with mTSCPC, three patients being treated with mTSCPC alone and three patients being treated with combination of mTSCPC and subconjunctival bevacizumab. The intraocular pressure (IOP), visual acuity, number of medications were monitored for 6 months. Complications that include visual acuity decline, prolonged anterior chamber inflammation and ocular pain were evaluated during the 6 months follow-up. No significant difference was found between the two groups at baseline (p = 0.82) or final follow up (p = 1) regarding the IOP reduction; neovascularisation regression was observed only in the combined therapy group (66.6%). Micropulse transscleral cyclophotocoagulation with diode laser is an effective method of lowering intraocular pressure in cases of refractory glaucoma, with minimal ocular complications. Additionally, the association between mTSCPC and subconjunctival bevacizumab resulted in neovascularisation regression and IOP reduction.